Several countries pause AstraZeneca vaccinations after growing cases of blood clotting

With many countries receiving a large supply of covid vaccines from numerous suppliers like Pfizer, Moderna, and Johnson & Johnson, several countries have paused AstraZeneca vaccinations after bloom embolism cases grow.

Thailand is the first Asian country to suspend use of the AstraZeneca vaccine. Even with European Medicines Agency’s reassurance that the vaccine is safe, users have seen over 30 cases of recipients having severe cases of blood embolism. These cases seem to be frightening possible vaccine recipients, because these cases have appeared hours and days after some individuals have received the AstraZeneca vaccine. Some health officials have stated that the COVID-19 can in fact “make blood cells more likely to clump up and form clots”.

AstraZeneca stated the vaccine was under extensive review during Phase 3 trials and peer-reviewed data confirms the shot is “generally well tolerated.” Those involved with the study and roll out were the University partner Oxford. Since last week there have now been over 5 million vaccine recipients in Europe alone. The number of 30 cases referenced earlier are part of the European statistics.

The reason for countries pausing the AstraZeneca vaccine is due to their extra precautions taken to safely investigate, then once completed they will resume with their extensive program to vaccinate as many of their citizens as possible. Many critics and people have been alarmed by the number of cases of blood clots among patients. But the EMA’S study and investigation have brought results showing that there are no more cases of blood clots among persons vaccinated and of the general population.




Leave a Reply